Status:

UNKNOWN

N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS

Lead Sponsor:

Angelini Farmacéutica

Collaborating Sponsors:

Sistemas Genómicos

Conditions:

In Vitro Fertilization

Controlled Ovarian Stimulation

Eligibility:

FEMALE

18-37 years

Brief Summary

This project wants to determinate whether there is a relationship between the N680S polymorphism genotype of the FSHR gene and the nature of the FSH used in controlled ovarian stimulation. It is a no...

Detailed Description

The investigators want to investigate whether the N680S polymorphism of the FSRH gene could affects ovarian response with different nature of the FSH used (human FSH and recombinant FSH) in patients u...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Signature of Informed Consent
  • Age ≤ 37 years
  • BMI \< 30 kg/m2
  • Antral follicles count 1st cycle COS = 5-15
  • Antimüllerian hormone basal 1st cycle COS \> 1,1 ng/ml and \< 3,1 ng/ml
  • COS protocol: equal starting dose in the 2 cycles of COS (150-225 UI/day) with dose adjustment from the 5th day of COS; pituitary suppression protocol in the 2 cycles of COS with GnRH antagonist with onset when ≥ 1 follicle of ≥ 14 mm in diameter or E2 ≤ 600 pg/ml; and triggering with hCGr or GnRH agonist
  • Optional the use of oral contraceptives (OC) (however, same in the 2 cycles)
  • 4-9 recovered oocytes in the 1st cycle of COS
  • ≤ 6 months between the 2 cycles of COS
  • Exclusion criteria:
  • Use of the LH activity during the cycles of COS
  • Presence of severe male factor
  • Grade III-IV endometriosis
  • Patients with polycystic ovary syndrome, a history of uterine or ovarian surgeries, hydrosalpinx visible by ultrasound, or uterine fibroids measuring \> 30 mm
  • Major systemic or uncontrolled endocrine-metabolic diseases affecting the pituitary gland, the thyroid gland, the adrenal glands, the pancreas, the liver, or the kidneys

Exclusion

    Key Trial Info

    Start Date :

    September 25 2019

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    June 1 2020

    Estimated Enrollment :

    300 Patients enrolled

    Trial Details

    Trial ID

    NCT04122729

    Start Date

    September 25 2019

    End Date

    June 1 2020

    Last Update

    October 10 2019

    Active Locations (12)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (12 locations)

    1

    Hospital Universitario Fundación Alcorcón

    Alcorcón, Madrid, Spain

    2

    Hospital Clínic

    Barcelona, Spain

    3

    Hospital Universitario Vall d'Hebron

    Barcelona, Spain

    4

    Hospital Universitario Reina Sofía

    Córdoba, Spain